Daniel Faga, AnaptysBio interim CEO
In wake of third straight mid-stage setback, AnaptysBio looks to punt IL-36 drug — even as PhIII goes on
Despite a new Phase II flop, AnaptysBio says it remains “optimistic” on its lead drug — it just doesn’t want to be the one taking the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
